227 related articles for article (PubMed ID: 30293664)
1. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study.
Rambarat CA; Elgendy IY; Handberg EM; Bairey Merz CN; Wei J; Minissian MB; Nelson MD; Thomson LEJ; Berman DS; Shaw LJ; Cook-Wiens G; Pepine CJ
Int J Cardiol; 2019 Feb; 276():8-13. PubMed ID: 30293664
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function.
Shah NR; Cheezum MK; Veeranna V; Horgan SJ; Taqueti VR; Murthy VL; Foster C; Hainer J; Daniels KM; Rivero J; Shah AM; Stone PH; Morrow DA; Steigner ML; Dorbala S; Blankstein R; Di Carli MF
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473401
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
[TBL] [Abstract][Full Text] [Related]
6. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.
Tagliamonte E; Rigo F; Cirillo T; Astarita C; Quaranta G; Marinelli U; Caruso A; Romano C; Capuano N
Echocardiography; 2015 Mar; 32(3):516-21. PubMed ID: 25041234
[TBL] [Abstract][Full Text] [Related]
7. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
Venkataraman R; Belardinelli L; Blackburn B; Heo J; Iskandrian AE
JACC Cardiovasc Imaging; 2009 Nov; 2(11):1301-9. PubMed ID: 19909934
[TBL] [Abstract][Full Text] [Related]
8. Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1-Year Follow-Up: Results From WISE-CVD.
Quesada O; Hermel M; Suppogu N; Aldiwani H; Shufelt C; Mehta PK; Cook-Wiens G; Maughan J; Berman DS; Thomson LEJ; Handberg EM; Pepine CJ; Bairey Merz CN; Wei J
J Am Heart Assoc; 2020 Jul; 9(13):e016305. PubMed ID: 32578481
[TBL] [Abstract][Full Text] [Related]
9. Angina relates to coronary flow in women with ischemia and no obstructive coronary artery disease.
Suppogu N; Wei J; Quesada O; Shufelt C; Cook-Wiens G; Samuels B; Petersen JW; Anderson RD; Handberg EM; Pepine CJ; Bairey Merz CN
Int J Cardiol; 2021 Jun; 333():35-39. PubMed ID: 33662486
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular concentric remodelling and functional impairment in women with ischaemia with no obstructive coronary artery disease and intermediate coronary flow reserve: a report from the WISE-CVD study.
Park SM; Wei J; Cook-Wiens G; Nelson MD; Thomson L; Berman D; Handberg E; Petersen J; Anderson D; Pepine CJ; Merz CNB
Eur Heart J Cardiovasc Imaging; 2019 Aug; 20(8):875-882. PubMed ID: 30904924
[TBL] [Abstract][Full Text] [Related]
11. Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study.
Denardo SJ; Wen X; Handberg EM; Bairey Merz CN; Sopko GS; Cooper-Dehoff RM; Pepine CJ
Clin Cardiol; 2011 Aug; 34(8):483-7. PubMed ID: 21780138
[TBL] [Abstract][Full Text] [Related]
12. Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine.
Nelson MD; Sharif B; Shaw JL; Cook-Wiens G; Wei J; Shufelt C; Mehta PK; Thomson LEJ; Berman DS; Thompson RB; Handberg EM; Pepine CJ; Li D; Bairey Merz CN
Clin Cardiol; 2017 May; 40(5):300-306. PubMed ID: 28004395
[TBL] [Abstract][Full Text] [Related]
13. Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women's Ischemia Syndrome Evaluation.
Thomson LE; Wei J; Agarwal M; Haft-Baradaran A; Shufelt C; Mehta PK; Gill EB; Johnson BD; Kenkre T; Handberg EM; Li D; Sharif B; Berman DS; Petersen JW; Pepine CJ; Bairey Merz CN
Circ Cardiovasc Imaging; 2015 Apr; 8(4):. PubMed ID: 25801710
[TBL] [Abstract][Full Text] [Related]
14. Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial.
Birkeland K; Khandwalla RM; Kedan I; Shufelt CL; Mehta PK; Minissian MB; Wei J; Handberg EM; Thomson LE; Berman DS; Petersen JW; Anderson RD; Cook-Wiens G; Pepine CJ; Bairey Merz CN
JMIR Res Protoc; 2017 Dec; 6(12):e255. PubMed ID: 29263019
[TBL] [Abstract][Full Text] [Related]
15. Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
Koh JS; Hung OY; Eshtehardi P; Kumar A; Rabah R; Raad M; Kumar S; Chaudhry S; Gupta S; Hosseini H; Brilakis E; Corban M; Sabbak N; Burnett GM; Liu C; Mehta PK; Quyyumi AA; Samady H
Circ Cardiovasc Interv; 2020 Dec; 13(12):e008204. PubMed ID: 33272036
[TBL] [Abstract][Full Text] [Related]
16. Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve.
Johnson NP; Gould KL
JACC Cardiovasc Imaging; 2011 Sep; 4(9):990-8. PubMed ID: 21920337
[TBL] [Abstract][Full Text] [Related]
17. Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study.
Mygind ND; Michelsen MM; Pena A; Qayyum AA; Frestad D; Christensen TE; Ghotbi AA; Dose N; Faber R; Vejlstrup N; Hasbak P; Kjaer A; Prescott E; Kastrup J;
J Cardiovasc Magn Reson; 2016 Nov; 18(1):76. PubMed ID: 27809867
[TBL] [Abstract][Full Text] [Related]
18. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE).
Pauly DF; Johnson BD; Anderson RD; Handberg EM; Smith KM; Cooper-DeHoff RM; Sopko G; Sharaf BM; Kelsey SF; Merz CN; Pepine CJ
Am Heart J; 2011 Oct; 162(4):678-84. PubMed ID: 21982660
[TBL] [Abstract][Full Text] [Related]
19. Inverse association of MRI-derived native myocardial T1 and perfusion reserve index in women with evidence of ischemia and no obstructive CAD: A pilot study.
Shaw JL; Nelson MD; Wei J; Motwani M; Landes S; Mehta PK; Thomson LEJ; Berman DS; Li D; Bairey Merz CN; Sharif B
Int J Cardiol; 2018 Nov; 270():48-53. PubMed ID: 30041981
[TBL] [Abstract][Full Text] [Related]
20. ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
Sinha A; Rahman H; Douiri A; Demir OM; De Silva K; Clapp B; Webb I; Gulati A; Pinho P; Dutta U; Ellis H; Shah AM; Chiribiri A; Marber M; Webb AJ; Perera D
Circulation; 2024 Jan; 149(1):36-47. PubMed ID: 37905403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
